Data Bytes: Bayer building women’s health portfolio

Bayer’s takeout of  KaNDy Therapeutics Ltd. this week is the pharma’s third deal in women’s health this year. In the past decade, the company has closed at least seven R&D, M&A or in-licensing agreements in the field.

Bayer AG (Xetra:BAYN) is acquiring the menopause play for $425 million up front and up to $450 million in development milestones, plus undisclosed sales milestones in the triple digits (see “Single-asset KaNDy Finds Exit”)...